top of page

ENHANCING AN
ANCIENT MOLECULE
FOR MODERN DAY THERAPEUTICS

Rewriting the Genetic Blueprint:

Best-In-Class Therapeutics Unlocked with

Synthetic Amino Acids

Delivering on the promise of antibody-conjugates and protein therapeutics

BrickBio's industry-leading technology empowers the precise customization of proteins to develop unrivaled biologics with an unprecedented therapeutic window for improved patient outcomes. The core technology enables first-in-class mammalian expression platforms using evolved versions of ancient tRNA molecules for homogenous, site-specific incorporation of synthetic amino acid conjugation handles into novel, optimized sites in any protein backbone

HomePage Tec

 Therapeutics have relied on suboptimal conjugation methods, resulting in a staggering number of failed therapeutics due to heterogeneity, lack of stability, or lack of precise control of the conjugation site.

ETRNAL Platform
The Evolved tRNA Localization Platform
 solves these limitations

Optimal Conjugation Sites for Best-in-Class Molecules

BrickBio Identifies Stable Conjugation Sites to

Shield ADC Payloads and Optimize their Activity

Site accessible.png
  • BrickBio mammalian expression systems enable efficient synthetic amino acid (conjugation handle) incorporation at any site within a protein backbone

  • The Evolved tRNA Localization (ETRNAL) Platform enables 10x more efficient machinery for synthetic amino acid incorporation and more diverse, efficient chemistries

  • Existing conjugation technologies with unstable and limited sites lead to poor clinical outcomes

  • Stable sites with BrickBio chemistry can shield undesired properties (i.e. toxicity)

  • Previously inaccessible sites enable unprecedented biophysical characteristics

Translates to Safer, More Efficacious Therapeutics

BrickBio ADCs are 5x safer and more efficacious than

other conjugation strategies with the same linker-payload

TI 20240124.png
  • BrickADC therapeutic index outcompetes cysteine, other site-specific conjugation technologies, and FDA approved ADCs.

  • Improvements derived from: Stable Conjugation, Reduced HydrophobicityTuned Exposure, Lower Hydrodynamic Radius, Optimized Cleavage KineticsAdditional Biophysical Optimization

High-Throughput Site Prediction for Any Payload

Site-Selection Panel Algorithm is Driven by Thousands

of Empirical and Literature-Backed Data Points for Any Payload Structure

site selection 2.png
  • Wet-lab data for all BrickADCs and literature data are compiled into proprietary data set

  • New or existing payload structures can be analyzed for optimal conjugation sites in silico (see above) and rapidly tested in vitro/in vivo

  • Reproducible prediction demonstrated with partnered and internal assets

Expand the ADC Status Quo: Multi-Payload Conjugates

Combine multiple distinct payloads with synergistic mechanisms of action

for unprecedented patient outcomes

multipayload.png
  • Multi-payload conjugation is performed in a one-pot reaction providing a simplified CMC process

  • First-in-Class stable CHO cell line for commercial scalability

  • Addresses unmet need: payload resistance, low efficacy, incomplete cancer immunity cycle

TECH

Pipeline Snapshot

pipeline.png
Pipeline

RECENT NEWS

RECENT NEWS

Management Team

CEO, CO-FOUNDER,

TIGER GENE

VP, COMMERCIAL

DEVELOPMENT

SENIOR ADVISOR &

CHAIRMAN OF SAB

HEAD OF BUSINESS DEVELOPMENT

CHIEF SCIENTIFIC

OFFICER

OUR TEAM

Careers

Join our team!

At BrickBio, our highly collaborative team drives to make an impact in patient's lives through our revolutionary platform technologies. We're looking for determined leaders in biotech who are passionate, innovative, and want to set the bar high for the next generation of protein therapeutics.

Careers

CONTACT
BRICKBIO

OUR ADDRESS

600 Winter Street

Waltham, MA, 02451, USA

For any general inquiries, please fill in the following contact form:

Thanks! We'll be in touch shortly.

contact

© 2019 BrickBio, Inc.

bottom of page